Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May;46(5):1039-1042.
doi: 10.1007/s00134-020-05951-5. Epub 2020 Feb 20.

Antimicrobial de-escalation is part of appropriate antibiotic usage in ICU

Jean-Francois Timsit  1   2 , Jeffrey Lipman  3   4   5 , Matteo Bassetti  6
Affiliations
Editorial

Antimicrobial de-escalation is part of appropriate antibiotic usage in ICU

Jean-Francois Timsit et al. Intensive Care Med. 2020 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JFT declares COI outside of the submitted work: scientific board: Pfizer, Paratek, Nabriva, Merck; MedImune, research grants to my university: Pfizer, Merck, Biomerieux, 3M; lectures fees: Merck, Pfizer, Biomerieux, Gilead. Academic Research program on rapid diagnostic tests (Multicap: NCT 03452826; PHRC 16-0595) and PK optimization in ICU (BICCS PHRC-18-0316). JL has received honoraria from MSD and Pfizer. MB declares outside of the submitted work has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, Bayer, Basilea, Biomerieux, Cidara, Gilead, Menarini, MSD, Nabriva, Paratek, Pfizer, Roche, Melinta, Shionogi, Tetraphase, VenatoRx and Vifor and has received study grants from Angelini, Basilea, Astellas, Shionogi, Cidara, Melinta, Gilead, Pfizer and MSD.

Figures

Fig. 1
Fig. 1
Key elements of antimicrobial use rationalization therapy and proposal of process quality indicators. EOT end-of-therapy, AB antibiotic, MDRB multidrug-resistant bacteria, MIC minimum inhibitory concentrations, RRT renal replacement therapy, TDM therapeutic drug monitoring, AE adverse event, PK pharmacokinetic
See this image and copyright information in PMC

Comment on

References

    1. Denny KJ, De Wale J, Laupland KB, Harris PNA, Lipman J. When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit. Clin Microbiol Infect. 2020;26:35–40. doi: 10.1016/j.cmi.2019.07.007. - DOI - PubMed
    1. Timsit JF, Bassetti M, Cremer O, Daikos G, de Waele J, Kallil A, Kipnis E, Kollef M, Laupland K, Paiva JA, Rodriguez-Bano J, Ruppe E, Salluh J, Taccone FS, Weiss E, Barbier F. Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Med. 2019;45:172–189. doi: 10.1007/s00134-019-05520-5. - DOI - PubMed
    1. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, Jarlier V, Nathwani D, Goossens H. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6:e619–e629. doi: 10.1016/S2214-109X(18)30186-4. - DOI - PubMed
    1. Patrier J, Timsit JF. Carbapenem use in critically ill patients. Curr Opin Infect Dis. 2020;33:86–91. doi: 10.1097/QCO.0000000000000622. - DOI - PubMed
    1. De Waele JJ, Schouten J, Beovic B, Tabah A, Leone M. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions–a viewpoint of experts. Intensive Care Med. 2020 doi: 10.1007/s00134-019-05871-z. - DOI - PMC - PubMed

Substances

LinkOut - more resources